The publication showed that these two cut-offs define a subset of subjects (13.5–35.7 CL) characterized by pre-AD dementia levels of amyloid burden that precede other biomarkers, such as tau deposition or clinical symptoms and accelerated amyloid accumulation. This evidence concerns the gene MAPT and Alzheimer disease.